Misoprostol emerges as a cost-effective, thermostable uterotonic alternative to oxytocin for Cesarean section hemorrhage prevention.

Postpartum hemorrhage (PPH) remains a leading cause of maternal morbidity and mortality globally, with Cesarean sections incurring an average blood loss of 1000 ml. While oxytocin is the first-line uterotonic, its use can be problematic in compromised patients due to adverse cardiovascular and antiplatelet effects. There's a critical need for effective, safe, and accessible alternatives to prevent uterine atony and reduce transfusion risks.

The provided text serves as an introductory overview of uterotonics for reducing bleeding during Cesarean section, discussing the general landscape of postpartum hemorrhage prevention. It does not detail the specific methodology, study design, participant numbers, or intervention protocols of a particular research study. Therefore, specific information regarding doses, routes, frequencies, or primary endpoints for a single investigation is not available within this record.

This introductory text highlights that postpartum hemorrhage affects approximately 6% of Cesarean births. It notes that routine oxytocin use significantly reduces PPH, but its side effects, including increased heart rate and negative inotropic effects, make it less ideal for patients with preeclampsia or cardiac disease. > Misoprostol, a prostaglandin E1 analogue, effectively stimulates the myometrium by binding to prostanoid receptors, proving effective in PPH prevention via oral or rectal routes. Its high bioavailability via sublingual administration and its cost-effectiveness and thermostability make it a valuable alternative, especially in developing countries.